Kansas City Business Journal: Kansas City-Led Clinical Trial on Popular Weight-Loss Drug is Honored as a 'Breakthrough of the Year'

 1 minute

A groundbreaking study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named the scientific breakthrough of the year by Science Magazine. The study revealed the popular weight loss drug semaglutide — commonly known as Ozempic and Wegovy — is highly effective at treating heart failure in patients with obesity.

The results of the STEP-HFpEF study are likely to be a paradigm shift in treating these patients. The study was the leading presentation at the European Society of Cardiology (ESC) 2023 Congress, the largest cardiovascular conference in the world.